207 related articles for article (PubMed ID: 26036945)
1. Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: A systematic review.
Pellegrino P; Radice S; Clementi E
Vaccine; 2015 Jul; 33(30):3444-9. PubMed ID: 26036945
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
3. On the relationship between human papilloma virus vaccine and autoimmune diseases.
Pellegrino P; Carnovale C; Pozzi M; Antoniazzi S; Perrone V; Salvati D; Gentili M; Brusadelli T; Clementi E; Radice S
Autoimmun Rev; 2014 Jul; 13(7):736-41. PubMed ID: 24468416
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
[TBL] [Abstract][Full Text] [Related]
5. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
7. Ecological validity of cost-effectiveness models of universal HPV vaccination: A systematic literature review.
Favato G; Easton T; Vecchiato R; Noikokyris E
Vaccine; 2017 May; 35(20):2622-2632. PubMed ID: 28408119
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
9. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
[TBL] [Abstract][Full Text] [Related]
11. HPV vaccines and lupus: current approaches towards preventing adverse immune cross-reactivity.
Bragazzi NL; Bridgewood C; Sharif K; Kamal M; Amital H; Watad A; Shoenfeld Y
Expert Rev Vaccines; 2019 Jan; 18(1):31-42. PubMed ID: 30526148
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
13. Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.
Ben Hadj Yahia MB; Jouin-Bortolotti A; Dervaux B
Clin Drug Investig; 2015 Aug; 35(8):471-85. PubMed ID: 26187455
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis.
Esposito S; Corona F; Barzon L; Cuoco F; Squarzon L; Marcati G; Torcoletti M; Gambino M; Palù G; Principi N
Expert Rev Vaccines; 2014 Nov; 13(11):1387-93. PubMed ID: 25066387
[TBL] [Abstract][Full Text] [Related]
16. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
Insinga RP; Dasbach EJ; Elbasha EH
Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
[TBL] [Abstract][Full Text] [Related]
17. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
18. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
